Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
5 "Calcium"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Articles
Gastrointestinal cancer
Adherence to the Recommended Intake of Calcium and Colorectal Cancer Risk in the HEXA Study
Jeeyoo Lee, Aesun Shin, Ji-Yeob Choi, Daehee Kang, Jong-Koo Lee
Cancer Res Treat. 2021;53(1):140-147.   Published online August 25, 2020
DOI: https://doi.org/10.4143/crt.2020.480
AbstractAbstract PDFPubReaderePub
Purpose
Dietary calcium intake has been suggested to be protective against the development of colorectal cancer. The mean dietary calcium intake of Koreans is 490 mg/day, which is far below the recommended calcium intake of 700-800 mg/day. In this study, we explored the relationship between dietary calcium intake and colorectal cancer development in Koreans with relatively low calcium intake compared with individuals in Western countries.
Materials and Methods
The Health Examinees Study, a large-scale genomic community-based prospective cohort study, was designed to identify the general characteristics of major chronic diseases in Koreans. A total of 119,501 participants aged 40-69 years recruited between 2004 and 2013 were included in this analysis. The calcium intake level was categorized using the Dietary Reference Intakes for Koreans (KDRIs). The Cox proportional hazards regression model was used to estimate the hazard ratio (HR) and the corresponding 95% confidence intervals (CIs) for colorectal cancer risk, adjusting for potential confounders.
Results
In the multivariable-adjusted model, compared with the group that consumed less than the recommended amount of calcium, the group that consumed more than the recommended intake of calcium showed a significant reduction in the risk of colorectal cancer in women. (HR, 0.54; 95% CI, 0.31 to 0.95). Among men, however, no significant association was observed between dietary calcium intake and colorectal cancer risk (HR, 0.89; 95% CI, 0.54 to 1.45).
Conclusion
Korean women who adhere to the recommended intake of calcium showed a reduced risk of colorectal cancer.

Citations

Citations to this article as recorded by  
  • Implication of calcium supplementations in health and diseases with special focus on colorectal cancer
    Shahanavaj Khan, S. Needa Mosvi, Saeed Vohra, Nitesh Kumar Poddar
    Critical Reviews in Clinical Laboratory Sciences.2024; 61(6): 496.     CrossRef
  • The burden of colorectal cancer attributable to dietary risk in Middle East and North African from 1990 to 2019
    Yahya Pasdar, Fatemeh Khosravi Shadmani, Hawal Lateef Fateh, Davood Soleimani, Behrooz Hamzeh, Mojtaba Ghalandari, Behrooz Moloudpour, Mitra Darbandi
    Scientific Reports.2023;[Epub]     CrossRef
  • Dietary intake and cancer incidence in Korean adults: a systematic review and meta-analysis of observational studies
    Ji Hyun Kim, Shinyoung Jun, Jeongseon Kim
    Epidemiology and Health.2023; 45: e2023102.     CrossRef
  • Anti-colorectal cancer effects of seaweed-derived bioactive compounds
    Yunhua Fu, Dong Xie, Yinghao Zhu, Xinyue Zhang, Hao Yue, Kai Zhu, Zifeng Pi, Yulin Dai
    Frontiers in Medicine.2022;[Epub]     CrossRef
  • Osteosarcopenic adiposity syndrome update and the role of associated minerals and vitamins
    Jasminka Z. Ilich
    Proceedings of the Nutrition Society.2021; 80(3): 344.     CrossRef
  • 6,619 View
  • 151 Download
  • 5 Crossref
Close layer
Impact of Angiotensin Receptor Blockers, Beta Blockers, Calcium Channel Blockers and Thiazide Diuretics on Survival of Ovarian Cancer Patients
Min Ae Cho, Soo Young Jeong, Insuk Sohn, Myeong-Seon Kim, Jun Hyeok Kang, E Sun Paik, Yoo-Young Lee, Chel Hun Choi
Cancer Res Treat. 2020;52(2):645-654.   Published online January 16, 2020
DOI: https://doi.org/10.4143/crt.2019.509
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
We investigated the impact of four types of antihypertensive medications, angiotensin receptor blockers (ARBs), beta blockers (BBs; both selective and non-selective), calcium channel blockers (CCBs), and thiazide diuretics (TDs) on survival outcomes in epithelial ovarian cancer (EOC).
Materials and Methods
A single-institutional retrospective chart review of 878 patients with EOC was performed. Survival was compared according to use of the four antihypertensive medications during primary treatment. Propensity score matching (ratio 1:3) was performed to control possible associated covariates, such as age, International Federation of Gynecology and Obstetrics stage, residual status after primary debulking surgery, and co-morbidity.
Results
Among 878 patients, 56 patients (6.4%) were ARB users, 62 (7.1%) were BB users, 107 (12.2%) were CCBs users and 32 (3.6%) used TDs. Median progression-free survival (PFS) for ARB, BB, and CCB users was 37.8, 27.2, and 23.6 months compared with 33.6 months for non-users. ARB was associated with 35% decreased risk of disease progression (hazard ratio [HR], 0.65; 95% confidence interval [CI], 0.42 to 0.99; p=0.046) in multivariate analysis. After propensity score matching, median PFS for ARB users was 37.8 months and ARB use remained to be associated with lower recurrence rate in univariate (p=0.035) and multivariate analysis (HR, 0.60; 95% CI, 0.39 to 0.93; p=0.022).
Conclusion
In this study, ARBs use during primary treatment is associated with lower recurrence in EOC patients. However, CCBs, BBs, and TDs did not show beneficial impact.

Citations

Citations to this article as recorded by  
  • Evaluation of antihypertensive medications use and survival in patients with ovarian cancer: a population-based retrospective cohort study
    Rūta Everatt, Irena Kuzmickienė, Birutė Brasiūnienė, Ieva Vincerževskienė, Birutė Intaitė, Saulius Cicėnas, Ingrida Lisauskienė
    BMC Women's Health.2024;[Epub]     CrossRef
  • Advanced progress of the relationship between renin–angiotensin–aldosterone system inhibitors and cancers
    Ruixing Zhang, Hongtao Yin, Mengdi Yang, Jinjin Liu, Donghu Zhen, Zheng Zhang
    Journal of Hypertension.2024; 42(11): 1862.     CrossRef
  • Impact of ACEI/ARB use on the survival of hypertensive patients with cancer: A meta‑analysis
    Yao Xiao, Xinlong Chen, Wancheng Li, Xin Li, Wence Zhou
    Oncology Letters.2024;[Epub]     CrossRef
  • Renin-Angiotensin-Aldosterone System Inhibitors and Development of Gynecologic Cancers: A 23 Million Individual Population-Based Study
    Nhi Thi Hong Nguyen, Phung-Anh Nguyen, Chih-Wei Huang, Ching-Huan Wang, Ming-Chin Lin, Min-Huei Hsu, Hoang Bui Bao, Shuo-Chen Chien, Hsuan-Chia Yang
    International Journal of Molecular Sciences.2023; 24(4): 3814.     CrossRef
  • Association of Hypertension and Breast Cancer: Antihypertensive Drugs as an Effective Adjunctive in Breast Cancer Therapy
    Yuanyuan Fan, Nazeer Hussain Khan, Muhammad Farhan Ali Khan, MD Faysal Ahammad, Tayyaba Zulfiqar, Razia Virk, Enshe Jiang
    Cancer Management and Research.2022; Volume 14: 1323.     CrossRef
  • The effect of angiotensin receptor blockers and angiotensin-converting enzyme inhibitors on progression of gastric cancer: systematic review and meta-analysis
    Seyed Ali Mehrdad, Farshad Mirzavi, Seyed Mohammad Reza Seyedi, Ahmad Asoodeh
    Anti-Cancer Drugs.2022; 33(10): 983.     CrossRef
  • Repurposing approved drugs for cancer therapy
    Catherine H Schein
    British Medical Bulletin.2021; 137(1): 13.     CrossRef
  • Norepinephrine inhibits migration and invasion of human glioblastoma cell cultures possibly via MMP-11 inhibition
    Jing Zhong, Weiran Shan, Zhiyi Zuo
    Brain Research.2021; 1756: 147280.     CrossRef
  • Antihypertensive Drug Use and the Risk of Ovarian Cancer Death among Finnish Ovarian Cancer Patients—A Nationwide Cohort Study
    Eerik E. E. Santala, Miia Artama, Eero Pukkala, Kala Visvanathan, Synnöve Staff, Teemu J. Murtola
    Cancers.2021; 13(9): 2087.     CrossRef
  • The Use of Antihypertensive Drugs as Coadjuvant Therapy in Cancer
    José A. Carlos-Escalante, Marcela de Jesús-Sánchez, Alejandro Rivas-Castro, Pavel S. Pichardo-Rojas, Claudia Arce, Talia Wegman-Ostrosky
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Post-Diagnostic Beta Blocker Use and Prognosis of Ovarian Cancer: A Systematic Review and Meta-Analysis of 11 Cohort Studies With 20,274 Patients
    Zhao-Yan Wen, Song Gao, Ting-Ting Gong, Yu-Ting Jiang, Jia-Yu Zhang, Yu-Hong Zhao, Qi-Jun Wu
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Stress Hormones: Emerging Targets in Gynecological Cancers
    Guoqiang Chen, Lei Qiu, Jinghai Gao, Jing Wang, Jianhong Dang, Lingling Li, Zhijun Jin, Xiaojun Liu
    Frontiers in Cell and Developmental Biology.2021;[Epub]     CrossRef
  • The Effect of Local Renin Angiotensin System in the Common Types of Cancer
    Moudhi Almutlaq, Abir Abdullah Alamro, Hassan S. Alamri, Amani Ahmed Alghamdi, Tlili Barhoumi
    Frontiers in Endocrinology.2021;[Epub]     CrossRef
  • Does sympathetic nervous system modulate tumor progression? A narrative review of the literature
    Ioannis Stavropoulos, Angelos Sarantopoulos, Anastasios Liverezas
    Journal of Drug Assessment.2020; 9(1): 106.     CrossRef
  • 13,824 View
  • 162 Download
  • 16 Web of Science
  • 14 Crossref
Close layer
Increased Risk of Osteoporosis in Gastric Cancer Survivors Compared to General Population Control: A Study with Representative Korean Population
Su-Min Jeong, Dong Wook Shin, Ji Eun Lee, Sang-Man Jin, Sung Kim
Cancer Res Treat. 2019;51(2):530-537.   Published online June 27, 2018
DOI: https://doi.org/10.4143/crt.2018.164
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Although several studies have suggested that osteoporosis is common in survivors of gastric cancer (GC), no study to date has directly assessed the risk for osteoporosis in GC survivors compared to matched controls. Thus, we aimed to investigate the relative risk for osteoporosis in survivors of GC compared to general population.
Materials and Methods
We used the Korea National Health and Nutrition Examination Survey data (2008-2011). Patients with a history of GC (n=94) were defined as case among 8,142 individuals over 50 years old who were evaluated by dual-energy X-ray absorptiometry. Controls (n=470) were matched to cases by age and sex in a 1:5 ratio. Osteopenia (–2.5 < T-score < –1.0) and osteoporosis (T-score ≤ –2.5) were defined.
Results
The prevalence of osteoporosis in GC survivors was 30.2%, which was significantly greater than that of controls (19.7%). In total, GC survivors had a 3.7-fold increased risk for osteoporosis compared to controls (p=0.021). In addition, the risk for osteoporosis of the total proximal femur total (TF) and femur neck (FN) was significantly increased among GC survivors compared to controls (adjusted relative risk, 4.64; 95% confidence interval, 1.16 to 18.6 in TF and adjusted relative risk, 3.58; 95% confidence interval, 1.19 to 10.8 in FN). Furthermore, we found sub-optimal daily calcium intake and mean serum levels of 25-hydroxy-vitamin D in both groups.
Conclusion
GC survivors are at significantly increased risk for osteoporosis, especially in the femur. Clinically, our finding supports the importance of screening bone health and adequate nutrient supplementation in survivors of GC.

Citations

Citations to this article as recorded by  
  • Senolytic treatment alleviates doxorubicin‐induced chemobrain
    Vivekananda Budamagunta, Ashok Kumar, Asha Rani, Sahana Manohar Sindhu, Yang Yang, Daohong Zhou, Thomas C. Foster
    Aging Cell.2024;[Epub]     CrossRef
  • Association between Gastric Cancer and Osteoporosis: A Longitudinal Follow-Up Study Using a National Health Sample Cohort
    Kyeong Min Han, Mi Jung Kwon, Joo-Hee Kim, Ji Hee Kim, Woo Jin Bang, Hyo Geun Choi, Dae Myoung Yoo, Na-Eun Lee, Nan Young Kim, Ho Suk Kang
    Cancers.2024; 16(13): 2291.     CrossRef
  • Preoperative abnormal bone mineral density as a prognostic indicator in patients undergoing gastrectomy for gastric cancer: A cohort study
    Soomin An, Wankyu Eo
    Medicine.2024; 103(21): e38251.     CrossRef
  • The risk of osteoporotic fracture in gastric cancer survivors: total gastrectomy versus subtotal gastrectomy versus endoscopic treatment
    HyunJin Oh, Byung-Ho Yoon, Jung-Wee Park, Ye Jhin Jeon, Bit-Na Yoo, Jean Kyung Bak, Yong-Chan Ha, Young-Kyun Lee
    Gastric Cancer.2023; 26(5): 814.     CrossRef
  • Factors Associated with Dietary Habit Changes in Korean Stomach Cancer Survivors after Cancer Treatment
    Junhee Park, Jiyoung Kim, Dong Wook Shin, Jinyoung Shin, Belong Cho, Yun-Mi Song
    Nutrients.2023; 15(14): 3268.     CrossRef
  • Bone Fragility in Gastrointestinal Disorders
    Daniela Merlotti, Christian Mingiano, Roberto Valenti, Guido Cavati, Marco Calabrese, Filippo Pirrotta, Simone Bianciardi, Alberto Palazzuoli, Luigi Gennari
    International Journal of Molecular Sciences.2022; 23(5): 2713.     CrossRef
  • Vitamin D—The Nutritional Status of Post-Gastrectomy Gastric Cancer Patients—Systematic Review
    Tomasz Muszyński, Karina Polak, Aleksandra Frątczak, Bartosz Miziołek, Beata Bergler-Czop, Antoni Szczepanik
    Nutrients.2022; 14(13): 2712.     CrossRef
  • Bone Loss in Patients with Pancreatic Neuroendocrine Tumors
    He Tong, Miaomiao Wang, Jingjing Liu, Chuangen Guo, Zhongqiu Wang, Jianhua Wang, Xiao Chen
    Journal of Clinical Medicine.2022; 11(22): 6701.     CrossRef
  • The risk of osteoporotic fractures after gastrectomy: Findings from the Korean national sample cohort database (2002-2019)
    Il Yun, Kyungduk Hurh, Sung Hoon Jeong, Eun-Cheol Park, Sung-In Jang
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Incidence and risk factors of osteoporotic status in outpatients who underwent gastrectomy for gastric cancer
    Tsutomu Namikawa, Keiichiro Yokota, Jun Iwabu, Masaya Munekage, Sunao Uemura, Shigehiro Tsujii, Hiromichi Maeda, Hiroyuki Kitagawa, Takashi Karashima, Masamitsu Kumon, Keiji Inoue, Michiya Kobayashi, Kazuhiro Hanazaki
    JGH Open.2020; 4(5): 903.     CrossRef
  • Helicobacter pylori Related Diseases and Osteoporotic Fractures (Narrative Review)
    Leon Fisher, Alexander Fisher, Paul N Smith
    Journal of Clinical Medicine.2020; 9(10): 3253.     CrossRef
  • Increased Risk of Osteoporotic Fracture in Postgastrectomy Gastric Cancer Survivors Compared With Matched Controls: A Nationwide Cohort Study in Korea
    Dong Wook Shin, Beomseok Suh, Hyunsun Lim, Yun-Suhk Suh, Yoon Jin Choi, Su-Min Jeong, Jae Moon Yun, Sun Ok Song, Youngmin Park
    American Journal of Gastroenterology.2019; 114(11): 1735.     CrossRef
  • 8,744 View
  • 163 Download
  • 13 Web of Science
  • 12 Crossref
Close layer
Optimization and Limitation of Calcium Ionophore to Generate DCs from Acute Myeloid Leukemic Cells
Thanh-Nhan Nguyen Pham, Bo-Hwa Choi, Hyun-Kyu Kang, Chun-Chi Jin, Nguyen Hoang Tuyet Minh, Sang-Ki Kim, Jong-Hee Nam, Deok-Hwan Yang, Yeo-Kyeoung Kim, Hyeoung-Joon Kim, Ik-Joo Chung, Je-Jung Lee
Cancer Res Treat. 2007;39(4):175-180.   Published online December 31, 2007
DOI: https://doi.org/10.4143/crt.2007.39.4.175
AbstractAbstract PDFPubReaderePub
Purpose

Calcium ionophore (CI) is used to generate dendritic cells (DCs) from progenitor cells, monocytes, or leukemic cells. The aim of this study was to determine the optimal dose of CI and the appropriate length of cell culture required for acute myeloid leukemia (AML) cells and to evaluate the limitations associated with CI.

Materials and Methods

To generate leukemic DCs, leukemic cells (4×106 cells) from six AML patients were cultured with various concentrations of CI and/or IL-4 for 1, 2 or 3 days.

Results

Potent leukemic DCs were successfully generated from all AML patients, with an average number of 1.2×106 cells produced in the presence of CI (270 ng/ml) for 2 days. Several surface molecules were clearly upregulated in AML cells supplemented with CI and IL-4, but not CD11c. Leukemic DCs cultured with CI had a higher allogeneic T cell stimulatory capacity than untreated AML cells, but the addition of IL-4 did not augment the MLR activity of these cells. AML cells cultured with CI in the presence or absence of IL-4 showed increased levels of apoptosis in comparison to primary cultures of AML cells.

Conclusion

Although CI appears to be advantageous in terms of time and cost effectiveness, the results of the present study suggest that the marked induction of apoptosis by CI limits its application to the generation of DCs from AML cells.

Citations

Citations to this article as recorded by  
  • The plasticity and potential of leukemia cell lines to differentiate into dendritic cells
    QINGWEI GUO, LELING ZHANG, FU LI, GUOSHENG JIANG
    Oncology Letters.2012; 4(4): 595.     CrossRef
  • 9,172 View
  • 55 Download
  • 1 Crossref
Close layer
Studies on the Mechanism of Hypoxic Increase of VEGF Expression in the Hep3B Human Hepatoma Cells
Yoo Wook Kwon, Soo Kyung Bae, Jung Ae Kim, Kyu Won Kim, Byung Chae Park
J Korean Cancer Assoc. 1997;29(2):220-226.
AbstractAbstract PDF
PURPOSE
Hepatocellular carcinoma (HCC), a typical hypervasculized tumor is very sensitive to hypoxia and vascular endothelial growth factor (VEGF) has previously been identified to be up-regulated in response to hypoxia in several cell types. However, the molecular mechanisms by which hypoxia is sensed by the cells remain enigmatic. To investigate whether calcium and AP-1 are involved in hypoxia-sensing mechanism, we performed following experiments.
MATERIALS AND METHODS
Hep3B cells were grown in hypoxic condition. To assess cell viability, MTT assay was performed. To investigate the effect of calcium and AP-1, northern blot analysis was performed after treatment with BAPTA/AM.
RESULTS
The expression of VEGF was significantly up-regulated by hypoxia in Hep3B, hepatocellular carcinoma cell line. The increased expression of VEGF induced by hypoxia was blocked by the addition of BAPTA/AM, a cytosolic calcium chelator to the media. In addition, we found that the expression of c-jun protooncogene was also up-regulated by hypoxia. Hypoxic increase of c-jun expression was also normalized by the treatment with BAPTA/AM.
CONCLUSION
These results suggest that the increased expression of VEGF by hypoxia is mediated through the calcium and c-jun signalling pathway in the Hep3B human hepatoma cell lines.
  • 2,342 View
  • 15 Download
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP